throbber

`
`2’.“
`
`Vol 105, No 11, March 19, 2002
`ISSN 0009-7322
`http://cIrc.aha]ourna|siorq
`dflrculation.
`M105, no. 11 (Mar. 19 2002)
`General Collection
`W1 c1743
`2‘J02-03-26 13:49:41
`
`\xllL/Ll
`
`d
`
`American Heart
`
`Ass0c1at10n®
`
`Fighting Heart Disease and Stroke
`
`lation
`
`J () U R N A ll 0 I“
`
`'I‘ II E A M E R l (' A N H E A R 'l' A S S 0 (‘ l AT I () N
`
`=\.\_ g
`7///All\\\\\
`[Em
`LIBRARY or
`
`
`
`PROPERTY OF THE
`NATIONAL
`LlBRARY OF
`MEDICINE
`
`
`
`
`
`
`-\
`
`J w
`
`rung w/Iiu lin’rlw 11/1 .vmur»
`
`I Circulation Electronic Pages
`l’clus With ’l‘ransposition ol‘thc (ircat Artcrics‘k
`Aluijv 7' Dunn/I'm. .illl).
`('ardiovascnlar Ncws‘k
`
`1’65 UM)
`
`I Clinician Update
`()ral Anticoagulation l'orAcntc ('oronary Syndrontcs
`Man .1. [immi'wj ill): l‘i'uv/i' llfll li’r'liuiigl. .l/l). I’ll/)HJJW
`I Brief Rapid Communications
`’l'rcatnicnl ol‘/\mImlaronc—Induced 'l'hyrotoxiwsis
`l’uia'l (Irma/r .l/h‘. “Rt 'l? i'! u/..................................... 1375
`laxprcssion of“ -l Receptor Antagonist by Plasmid DNA
`Ili'lmgrkmm Inn, 1151*. 1'! ul .......................................... 1375’
`('alhclcr-llascd |zmiomyocartiial Injection With \rlRl
`RUIN’I‘IJ. [it'llt’l‘llllllI‘ HI), ('1 il/.
`
`I783
`
`I‘Clinical Investigation and Reports
`l'i'ial ol‘a Distal l‘ililWUllL‘ Protection Dcvicc®
`IJH‘D'
`, 777777
`I’tlllll/tl .\' Urn/Ir .\I/). (’l ill,
`.........
`.........
`Angiogcnlc (lL‘llL‘ l'hcrap} Trial in l’alicnts \Nith Stable Angina
`(Wit/1' I. (fr/ma,
`\Il). d u/ ............................................ [39/
`li'li'cct UliA/lllll'tliii} cin on lintlothclial l’nnction
`Nil/Ill llut/nu'i‘.
`ll/\’( I? (I (ll .......................... [3943'
`\"cntin'iilal Res)nrhroni/alion
`luv/uni. Strum,
`\ll)‘ (I ll/ ............................................... [304
`l‘roinsnlin antl L'oronary llcart Discasc
`Jt'i'
`lining ()ll,
`.lll). ('1 u/ ........................................... l3/l
`l.\‘ll Ventricular Remodeling ML and Heart I-aililrc
`(h'ltli'irkl li'i'lill,
`ill). ('I (I,.............................................. [3/7
`
`Actions ol‘Ba: on Human liorcarm Blood |7lo\\
`Illa/Illt’lt‘ /)(Ill‘(‘,\'. I’lil). NRC/3 ('l u/ ................................. 1333’
`(‘arotid Sinus Dcncrvation in Humans
`xl/‘I/IHI'.-l../,
`.S‘mil, All). I’ll/J, ('1 Il/...................................... 133‘)
`l’roslhctic llcarl Valves in Dialysis Patients
`(War/('5' :1, ”(1:05; Ml). t’/ (l/ ............................................ I336
`Risk Stratification in Brugada Syndrome
`Silvia (is Prim/"i. Ml), I’ll/J, «I u/ ...................................... 1343
`Renal lill‘ccls ol'Adcnosinc Antagonist and Furoscmidc
`Sli'p/nw S. (full/ml), MI). Cl (1/........................................... [3’48
`Sympathetic Activity and Survival lIl IESRD
`('(n'mim' Xm‘i'iI/i, Jill), ('I (ll............................................... 135-!
`
`I Basic Science Reports
`l’ctal Athcrogcncsis and Aortic (icnc lzxprcssion ®
`(Yum/m Nupol/fl MI). ('I (l/ .............................................. [36!)
`[{ziliixilbiic Activates l‘l3K/Akl Pathway
`’Iimumm’u Sinmnri'ni. A ll), [VI/1 ('1 (ll............................... HON
`
`l’ropranolol and the Prevention olillcari liaihirc
`Mum/iii?) Hui. MI). ('I (II ........................................... I} 74
`('ariporulc and losarlan in llcart l’ailurc
`.lu/i /.’ l.()(’l1ll('{'/l(‘ll. Jill), (’I (II ........................................... IJ’NU
`
`I Clinical Cardiology: New Frontiers
`Diastolic llcarl l'ailurc
`.\Ii('/I(lt'l R Xi/i’, All); Dirk I“ It’rutvm'l'l, A II) ...... V
`
`V
`
`..... [357
`
`I Images in Cardiovascular Medicine
`Arrhythmogcnic Right Vcnlricular (‘ai’tliomyopathy
`./.;l,
`,\Ii‘( 'i'uIm/i. till). /’/Il). ('I (l/
`
`3‘04
`
`Page 1
`
`Medtronic Exhibit 1428
`
`Page 1
`
`Medtronic Exhibit 1428
`
`

`

`Circulation
`
`'JounNALjor JI‘IIE AMERICAN HEARTAssoctA'rION.
`
`
`
`
`
`WWW
`
`March 19, 2002
`
`Circulation Electronic Pages
`
`
`Images in Cardiovascular Medicine
`Premature Closure of the It‘oramen Ovale and Duetus Arteriosus in a Fetus With Transposition of the
`Great Arteries
`Mary T. Donofrio, MD
`
`..................................................... *e65-066
`
`Clinician Update
`
`Oral Anticoagulation for Acute Coronary Syndromes
`Marc A. Bronwer, MD; Freek WA, Ver/zeugt, MD, PhD .............................................. 1270
`
`Brief Rapid Communications
`Successful Treatment of Amiodarone-Induced Thyrotoxicosis
`Faizel Osman, Ml}, MRCI’; Jayne A. Franklyn, MD, PhD, FRCP; Michael C. Sheppard, PhD, FRCP;
`Michael D. Gurimmgc, MD. FRCP ................................................................ 1275
`Local Expression of Interleukin-I Receptor Antagonist hy Plasmid DNA Improves Mortality and Decreases
`Myocardial Inflammation in Experimental Coxsackieviral Myocarditis
`Byung-Kwan Lint, MSc; Seong-Choon Choc, MD, PhD; Jae—0k Shin, BSc; Seong-Hynn Ho, MSc;
`Jong-Mook Kim, PhD; Seung-Shin Yn, PhD; Sunyoung Kim, I’hD; Elm—Seek Jean, MD, PhD ................ 1278
`Catheter-Based Endomyoeardial Injection With Real-Time Magnetic Resonance Imaging
`Robert J. Lederman, MD; Michael A. Guttman, MSC,‘ Dana C. Peters, PhD; Richard B. Thompson, PhD;
`Jonathan M. Sorger, BS; Alexander J. Dick, MD; Venkatesh K. Raman, MD; Elliot R. McVeigh, PhD ......... 1282
`
`Clinical Investigation and Reports*
`Randomized Trial of a Distal Embolic Protection Device During Pereutaneous Intervention of Saphenous
`Vein Aorto-Coronary Bypass Grafts
`Donald S. Bainl. MD; Dennis Wahr, MD; Barry George, MD; Martin 8. Leon, MD; Joel Greenberg, MD;
`Donald E Ctttlip, MD; Unsal Kaya, MS; Jeffrey J. Pop/nu, MD; Kalon K.L. Ho, MD, MSe;
`Richard E. Kum‘z, MD, MSe; on behalf of the Saphenous vein graft Angioplasty Free of Emboli Randomized
`(SAFER) Trial Investigators ..................................................................... 1285©
`Angiogenie Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris
`Cindy L. Grines, MD; Matthew W. Watkins, MD; Greg Helmer, MD; William Penny, MD; Jeffrey Brinker, MD;
`Jonathan D. Murmur, MD; Andrew West, Ml); Jeffery J. Rade, MD; Pratt Marrott, MRCP, MSc;
`H. Kirk Hammond, MD; Robert L. Engler, MD ...................................................... 1291
`Effect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and
`Evidence of Chlamydia pneumoniae Infection
`Nikhil Pare/lure, MRCP,‘ Ennnanouil G. Zouridakis, MD; Juan Carlos Kaski, MD, DSc, FRCP ............. 1298
`
`*Supportcd in concept as prevention of cardiovascular disease by an unrestricted gift from Merck & Co. Plizer provides an unrestricted gift for
`subscriptions to Circulation for Cardiology Fellows in training.
`
`CIRCULATION (iSSN 00097322) is published weekly except combined the first two weeks in January and the last two weeks in December by Lippincott Williams & Wilkins at 16522
`Hunters Green Parkway, Hagerstown, MD 21740. Business offices are located at 530 Walnut Street, Philadelphia, PA 19106-3621. Production offices are located at 351 West Camden
`Street, Baltimore, MD 21201-2436. Individuals may subscribe for their personal use at the following rates: $206 for members of an American Heart Association scientific council and
`$275 for nonmembers; international: $353 for members of an American Heart Association scientific council and $471 for nonmembers. Periodicals postage paid at Hagerstewn, MD,
`and additional mailing offices. POSTMASTER: Send address changes to CIRCULATION, American Heart Association, Lippincott Williams & Wilkins, 16522 Hunters Green Parkway,
`
`Hagerstown, MD 21740.
`
`at. the FILM a nd may be
`in blect‘ US Copyright Laws
`
`Page 2
`
`Medtronic Exhibit 1428
`
`Page 2
`
`Medtronic Exhibit 1428
`
`

`

`Effects of Long-Term Biventricular Stimulation for Resynchronization on Echocardiographic
`Measures of Remodeling
`Leslie A. Saxon, MD; Teresa De Marco, MD; Jill Schafer, MS; Kanu Chatteijee, MB; Uday N. Kuniar, MD;
`Elyse Foster, MD; for the VIGOR Congestive Heart Failure Investigators ________________________________ 1304
`
`Sex Differences in the Association Between Proinsulin and Intact Insulin With Coronary Heart Disease in
`N0ndiabetic Older Adults: The Rancho Bernardo Study
`Jee-Young 0h, MD; Elizabeth Barrett-Connor, MD; Nicole M. Wedick, MS .............................. 1311
`
`Left Ventricular Volume Reduction by Radiofrcquency Heating of Chronic Myocardial Infarction in
`Patients With Congestive Heart Failure
`Octavio A. Victal, MD; John R. Teerlink, MD; Efrain Gaxiola, MD; Arthur W. Wallace, MD, PhD;
`Sergio Najar, MD; David H. Camacho, MD; Augustin Gutierrez, MD; Gabriel Herrera, MD;
`Gustavo Zuniga, MD; Fausto Mercado-Rios, MD; Mark B. Ratcliff'e, MD ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, 1317
`
`Barium Reduces Resting Blood Flow and Inhibits Potassium-Induced Vasodilation in the Human Forearm
`Matthew Dawes, PhD, MRCP; Christine Sieniawska, BSe, MPhil;
`Trevor Delves, PhD, CChem, EurClinChem, FRSC; Rahul Dwivedi, MRCP; Philip J. Chowienczyk, FRCI’:
`James M. River. MA, DP/u'L FRCP ............................................................... 1323
`
`Long-Term Effects of Carotid Sinus Denervation on Arterial Blood Pressure in Humans
`Arthur A.J. Smit, MD, PhD; Henri J.L.M. Timmers, MD; Woiaer Wieling, MD, PhD; Mariette Wagenaar, MD;
`Henri AM. Marres, MD, PhD; Jacques W.M. Lenders, MD, PhD; Gert A. van Montfrans, MD, PhD,-
`John M. Karemaker. PhD ....................................................................... 132‘)
`
`Long-Term Survival of Dialysis Patients in the United States With Prosthetic Heart Valves: Should
`ACC/AHA Practice Guidelines on Valve Selection Be Modified?
`Charles A. Herzog, MD; Jennie Z. Ma, PhD; Allan J. Collins. MD ..................................... 1336
`
`Natural History of Brugada Syndrome: Insights for Risk Stratification and Management
`Silvia G. Priori, MD, PhD; Carlo Napolitano, MD, PhD; Maurizio Gasparini. MD; Carlo Pappone, MI),-
`Paolo Della Bella, MD; Umberto Giordano, Ml); Raffaello Bloise, MD; Carla Giustetto, MD;
`Roberto De Nardis, MD; Massimiliano Grillo, MD; Elena Ronehetti, PhD; Giovanna Faggiano, MD,-
`Jami Nastoli. BS .............................................................................. 1342
`
`BG971‘) (CVT-124), an Al Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function
`Observed With Diuretic 'l‘herapy
`Stephen S. Gottlieb, MD; D. Craig Itrater, MD; Ignatius Thomas, MD; Edward Havranek, MD;
`Robert Bourge, MD; Steven Goldman, MI); Farere Dyer, MD; Miguel Gomez, MD; Donald Bennett, MD;
`Barry Ticho, MI); Evan Rec/anon, MD; William '1'. Abraham, MD ...................................... 1348
`
`Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage
`Renal Disease
`Carmine Zoccali, MD; Francesca Mallamaci, MD; Saverio I’arlongo, MI);
`Sebastiano Cutrupi; Francesco Antonio Benedetto, Ml); Giovanni ’I‘ripepi; Graziella Bonanno, M1);
`Francesco Rapisarda, Ml); Pasquale Fatuzzo, MD; Giuseppe Seminara, Ml);
`Alessandro Cateliotti; Benedetto Staneanelli, MD; Lorenzo Salvatore Malatino, MI) _______________________ 1354
`
`Basic Science Reports
`
`
`Maternal Hypercholesterolemia During Pregnancy Promotes Early Atherogenesis in LDL
`Receptor-Deficient Mice and Alters Aortic Gene Expression Determined by Microarray
`Claudio Napoli, MD; Filomena de Nigris, PhD; John S. Welch, BS; Federico B. Calara, PhD;
`Robert 0. Stuart, MD; Christopher K. Glass, MI); Wulf [’alinski. MD ................................. l360®
`
`Nongenomic Mechanisms of Endothelial Nitric Oxide Synthasc Activation by the Selective Estrogen
`Receptor Modulator Raloxifene
`Tommaso Simoncini, MD, PhD; Andrea R. Genazzani, MD, PM); James K. Liao, MI) ...................... l368
`
`Propranolol Prevents the Development of Heart Failure by Restoring FKBI’I2.6-Mediatc(l Stabilization of
`Ryanodine Receptor
`Masahiro Doi, MD; Masajumi Yano, MD, PhD; Shigeki Kobayashi, MD, PhD; Masateru Kohno, MI);
`Takahiro Tokuhisa, MD; Shinichi Okuda, MD; Masae Suetsugu, BS; Yuhji Hisaumtsu, MD, PhD;
`Tomoko Ohkusa, MD, PhD; Michihiro Kohno, MD, PhD; Masunori Matsuzaki, Ml), l’hl) ,,,,,,,,,,,,,,,,,,, 1374
`
`Page 3
`
`Medtronic Exhibit 1428
`
`Page 3
`
`Medtronic Exhibit 1428
`
`

`

`Effects of Cariporidc and Losartan on Hypertrophy, Calcium Transients, Contractility, and Gene
`Expression in Congestive lleart Failure
`Jan P. Locimccllcn, MD; Ulrik Wis/off," MSc, PhD; Geir Fri/ck, MD, PhD; (dyvind Ellingsen, MD, PhD ....... 1380
`
`Clinical Cardiology: New Frontiers
`
`
`New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I: Diagnosis, Prognosis, and
`Measurements of Diastolic Function
`Michael R. Zile, MD; Dirk L. Brutsaert, MD ........................................................ 1387
`
`
`Images in Cardiovascular Medicine
`
`Left Ventricular Involvement in Arrhythmogenic Right Ventricular Cardiomyopathy
`J,A. McCrolmn, MD, PhD; AS. John, MD; CH. Lorenz, PhD; S. W. Davies, MD; DJ. Pennell, MD __________ 1394
`
`
`Annotated Table of Contents ........................................................... A10
`
`Classified Advertising .................................................................
`
`Bl
`
`The cover figure is from the article in this issue by McCrohon et al. Figure 2. Tl-weighted turbo spin-echo images before
`the application of a fat saturation pulse over the region of interest. The arrows point to areas of fatty infiltration of the
`anterior and inferior myocardium from the epicardial surface. Fatty infiltration is continued by the nulling of these areas
`(black regions) using a fat saturation prepulse in the same plane. The RV free wall shows diffuse high signal consistent
`
`with fat (C). See p 1394.
`
`Page 4
`
`Medtronic Exhibit 1428
`
`Page 4
`
`Medtronic Exhibit 1428
`
`

`

`Clinical Investigation and Reports
`
`Randomized Trial of a Distal Embolic Protection Device
`During Percutaneous Intervention of Saphenous Vein
`Aorto-Coronary Bypass Grafts
`Donald S. Baim, MD; Dennis Wahr, MD; Barry George, MD; Martin B. Leon, MD;
`Joel Greenberg, MD; Donald E. Cutlip, MD; Unsal Kaya, MS; Jeffrey J. Popma, MD;
`Kalon K.L. Ho, MD, MSc; Richard E. Kuntz, MD, MSc; on behalf of the Saphenous vein graft
`Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators
`
`Background—Stents provide effective treatment for stenotic saphenous venous aorto-coronary bypass grafts, but their
`placement carries a 20% incidence of procedure-related complications, which potentially are related to the distal
`embolization of atherosclerotic debris. We report the first multicenter randomized trial to evaluate use of a distal embolic
`protection device during stenting of such lesions.
`Methods and Results—Of 801 eligible patients, 406 were randomly assigned to stent placement over the shaft of the distal
`protection device, and 395 were assigned to stent placement over a conventional 0.014-inch angioplasty guidewire
`(control group). The primary end point—a composite of death, myocardial infarction, emergency bypass, or target lesion
`revascularization by 30 days—was observed in 65 patients (16.5%) assigned to the control group and 39 patients (9.6%)
`assigned to the embolic protection device (P⫽0.004). This 42% relative reduction in major adverse cardiac events was
`driven by myocardial infarction (8.6% versus 14.7%, P⫽0.008) and “no-reflow” phenomenon (3% versus 9%, P⫽0.02).
`Clinical benefit was seen even when platelet glycoprotein IIb/IIIa receptor blockers were administered (61% of patients),
`with composite end points occurring in 10.7% of protection device patients versus 19.4% of control patients (P⫽0.008).
`Conclusions—Use of this distal protection device during stenting of stenotic venous grafts was associated with a highly
`significant reduction in major adverse events compared with stenting over a conventional angioplasty guidewire. This
`demonstrates the importance of distal embolization in causing major adverse cardiac events and the value of embolic
`protection devices in preventing such complications. (Circulation. 2002;105:1285-1290.)
`
`Key Words: embolism 䡲 grafting 䡲 stenosis 䡲 angioplasty 䡲 stents
`
`Catheter-based intervention in saphenous venous aorto-
`
`coronary bypass grafts carries a significant (⬇20%) risk
`of a major adverse clinical event (MACE) (predominantly
`myocardial infarction) or reduced antegrade flow (the no-
`reflow phenomenon).1 Several mechanisms have been of-
`fered, including spasm of the distal microcirculation, platelet
`clumping, and most recently, the distal embolization of pieces
`of friable lipid-rich plaque.2 Preliminary work with the
`PercuSurge GuardWire—a device for transient distal balloon
`occlusion during angioplasty or stent placement that allows
`recovery of any liberated plaque by aspiration before resto-
`ration of antegrade flow— has demonstrated consistent recov-
`ery of plaque constituents (cholesterol crystals, foam cells,
`fibrous plaque) that otherwise would have embolized into the
`myocardial bed.3 This initial experience has also suggested a
`
`reduced incidence of myocardial infarction (⬍6%) compared
`with the 20% historical rate of infarction seen without such
`distal protection.4 The Saphenous vein graft Angioplasty Free
`of Emboli Randomized (SAFER) trial was an 801-patient US
`multicenter study in which patients undergoing saphenous
`vein graft intervention were randomized to undergo either
`stenting with a conventional guidewire or stenting with the
`GuardWire distal protection device. The SAFER trial was the
`pivotal trial that led to US Food and Drug Administration
`approval in August 2001.
`
`Methods
`The primary objective of Saphenous vein graft Angioplasty Free of
`Emboli Randomized (SAFER) trial was to compare the 30-day
`clinical outcome after saphenous vein graft stenting plus GuardWire
`
`Received December 28, 2001; revision received January 31, 2002; accepted January 31, 2002.
`From the Division of Cardiovascular Diseases, Brigham and Women’s Hospital, Boston Mass (D.S.B., J.J.P., R.E.K.); Harvard Clinical Research
`Institute, Boston, Mass (D.S.B., D.E.C., U.K., K.K.L.H., R.E.K.); Riverside Hospital, Columbus, Ohio (B.G.); St Joseph’s Mercy Hospital, Ann Arbor,
`Mich (D.W.); Cardiovascular Research Foundation, Lenox Hill Hospital, New York, NY (M.B.L.); Florida Hospital, Orlando, Fla (J.G.); and Beth Israel
`Deaconess Medical Center, Boston, Mass (D.E.C., K.K.L.H.).
`Dr Leon served as a consultant to PercuSurge Corporation during the trial.
`This article originally appeared Online on February 25, 2002 (Circulation. 2002;105:r13–r18).
`Correspondence to Donald S. Baim, MD, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail dbaim@partners.org
`© 2002 American Heart Association, Inc.
`Circulation is available at http://www.circulationaha.org
`
`DOI: 10.1161/01.CIR.0000012783.63093.0C
`
`1285
`
`Downloaded from http://ahajournals.org by on July 8, 2019
`
`Page 5
`
`Medtronic Exhibit 1428
`
`

`

`1286
`
`Circulation
`
`March 19, 2002
`
`Figure 1. Diagram of the GuardWire device. A, The GuardWire is advanced from the guide catheter, through and beyond the saphe-
`nous vein graft (SVG) lesion. B, The compliant occlusion balloon at the GuardWire tip is inflated to occlude flow before the stent is
`deployed. C, After stent deployment, an Export catheter is advanced over the GuardWire and aspirated to remove stagnant column of
`blood with suspended embolic debris. D, The GuardWire balloon is deflated to restore antegrade blood flow.
`
`distal protection versus that performed over a conventional guide-
`wire (control arm). This randomized trial complied with the Decla-
`ration of Helsinki with regard to investigation in humans, was
`approved for Investigational Device Exemption by the US Food and
`Drug Administration, and was approved by the local hospital
`Institutional Review Boards at each of the investigational sites.
`
`Eligibility Criteria
`Patient candidates had a history of angina and signs of myocardial
`ischemia resulting from a target lesion ⬎50% diameter stenosis
`(angiographic visual assessment) located in the mid-portion of a
`saphenous vein graft, with a reference diameter between 3 and 6 mm.
`In the first 142 patients, the lesion could not occupy more than one
`third of the graft length. In subsequent patients, no upper limit on
`lesion length was imposed. Major exclusion criteria included (1)
`recent myocardial
`infarction with baseline elevation of cardiac
`enzymes (creatine kinase-MB fraction), (2) significantly impaired
`left ventricular function (ejection fraction ⬍25%), (3) baseline
`creatinine ⬎2.5 mg/dL (unless on long-term hemodialysis), and (4)
`planned use of an atherectomy device.
`
`Coronary Intervention
`After informed consent, patients were premedicated with aspirin
`(325 mg orally) and brought to the interventional laboratory. During
`the procedure, intravenous heparin was administered to prolong the
`activated clotting time to ⬎250 seconds. A platelet glycoprotein
`IIb/IIIa receptor blocker was used at the discretion of the operator.
`Subjects were randomized to undergo stenting performed over either
`
`a conventional 0.014-inch angioplasty guidewire or a 0.014-inch
`PercuSurge GuardWire balloon occlusion device, with randomiza-
`tion stratified by site and by whether the operator preselected IIb/IIIa
`receptor blockade.
`The series of treatments for both arms of the study involved
`optional pre-stent dilatation of the lesion, deployment of ⱖ1 stent,
`and optional post-stent dilatation (at higher pressure or with a larger
`diameter balloon). In patients assigned to the GuardWire arm (Figure
`1), the 0.014-inch hollow-core GuardWire was advanced across and
`beyond the target lesion and was attached to a proximal adaptor that
`allowed progressive inflation of the elastomeric balloon at its tip
`(range of inflated diameter, 3 to 6 mm) with dilute radiographic
`contrast until the antegrade flow of contrast within the graft was
`halted. The lumen of the GuardWire was then sealed, allowing
`removal of the adaptor and serial performance of the stent procedure
`(using the GuardWire shaft in lieu of a conventional guidewire).
`After satisfactory stent deployment, a 5F (1.7 mm) diameter aspira-
`tion catheter (Export) was advanced over the GuardWire until it lay
`just proximal to the occlusion balloon and was connected to an
`evacuated 20-cc syringe. Between 20 and 40 mL of blood was
`vigorously aspirated through this catheter before the adaptor was
`reattached and the distal occlusion balloon was deflated to restore
`antegrade flow.
`After satisfactory stent deployment, final angiograms were ob-
`tained. Standard post-stent therapy (aspirin 325 mg/d, clopidogrel
`300 mg oral load, followed by 75 mg/d for 2 to 4 weeks) was
`commenced. Serial 12-lead ECGs were performed after the proce-
`dure and daily until discharge, and blood samples for measurement
`
`Downloaded from http://ahajournals.org by on July 8, 2019
`
`Page 6
`
`Medtronic Exhibit 1428
`
`

`

`of serum creatine kinase (CK) and its myocardial (MB) fraction were
`collected after the procedure and every 8 hours thereafter until
`discharge.
`
`Data Collection and Core Laboratory Analysis
`Detailed case report forms were completed by the clinical coordina-
`tors at each site, monitored by independent study monitors, and
`submitted to the data-coordinating center (Harvard Clinical Research
`Institute, Harvard Medical School, Boston, Mass). Angiograms
`obtained during the procedure were submitted to the angiographic
`core laboratory (Brigham and Women’s Angiographic Core Labo-
`ratory, Boston, Mass), where they were analyzed with a computer-
`based system (Medis; Leiden, the Netherlands). The diameter of the
`reference coronary and the minimum lumen diameter of the target
`lesion were determined before the procedure, immediately after the
`procedure, and at follow-up.
`
`Study End Points and Statistical Methods
`The primary end point of the study, MACE rate at 30 days, was
`defined as the composite of death, myocardial infarction, emergent
`bypass surgery, or target vessel revascularization within 30 days of
`the index procedure. Death was defined as the occurrence of death
`from any cause. Myocardial infarction was defined as the occurrence
`of an elevated CK-MB fraction ⬎3⫻ the upper limit of normal
`(standardized to each clinical site’s normal range) in at least 1 of 3
`serial protocol-driven cardiac enzyme measurements performed
`during the first 18 to 24 hours after the index procedure or in any
`subsequent clinically driven measurement. Patients with enzymatic
`elevation were further divided into those with and without appear-
`ance of pathological Q waves on serial ECGs. A clinical events
`committee that was blinded to treatment assignment determined all
`clinical end points.
`Technical success for patients assigned to the GuardWire arm was
`defined as delivery of GuardWire system to the intended target site,
`followed by successful inflation, aspiration, and deflation according
`to the Instructions for Use. Other prespecified secondary end points
`included acute thrombosis, postprocedure flow, and vessel injury
`(distal dissection or perforation).
`The study was designed to reject the null hypothesis (ie, that there
`was no difference between the treatment groups) with a 2-tailed 5%
`level of significance and 80% power. On the basis of data from prior
`single-center vein graft intervention study,4 it was assumed that the
`30-day primary end point rate would be 16% in the control arm and
`ⱕ11% in the embolic protection arm. A group sequential analysis
`that allowed for 2 interim analyses and 1 final analysis was
`incorporated using the ␣-spending algorithm of Geller and Pocock.5
`Applying these assumptions and allowing for a 5% lost–to–
`follow-up rate,
`it was determined that 800 patients would be
`randomized, with interim analyses at 350 and 550 patients. The
`nominal probability value assigned for the 3 group sequential
`analyses was 0.014 for 350 subjects, 0.021 for 550 subjects, and
`0.030 for 800 subjects.
`All primary comparisons used the intent-to-treat principle. Con-
`tinuous variables were compared using Student’s t test if normally
`distributed and Wilcoxon rank-sum if not. Binary variables were
`compared using ␹2 with normal approximation or Fisher’s exact test
`when appropriate. A 2-tailed P value of 0.05 was considered
`significant. All statistical analyses were performed using the SAS,
`version 6.12 (SAS Institute, Cary, NC).
`
`Results
`Between June 1999 and August 2000, 801 patients were
`enrolled into the SAFER trial at 47 sites. After 492 patients
`were enrolled, the hospital discharge end point was com-
`pared. Because the difference between the 2 arms of the study
`did not reach the statistical threshold P value of 0.014, the
`trial was continued. At the time of the second interim Data
`and Safety Monitoring Committee review (after enrollment of
`692 patients),
`the required adjusted 2-sided P value
`
`Baim et al
`
`Distal Embolic Protection
`
`1287
`
`TABLE 1. Baseline Clinical Characteristics of 801 Patients
`With Saphenous Vein Graft Lesions Treated by Stenting
`Assigned to Receive GuardWire Embolic Protection or
`Conventional Guidewire
`
`Patient Characteristic
`
`GuardWire
`(n⫽406)
`68⫾10
`332 (82)
`134 (33)
`240 (61)
`46 (11)
`47.6⫾12.0
`303 (75)
`166 (41)
`156 (39)
`
`Control
`(n⫽395)
`69⫾9
`331 (84)
`133 (34)
`248 (64)
`50 (13)
`47.0⫾12.1
`299 (76)
`156 (40)
`156 (40)
`
`Age, y
`Male sex
`Diabetes mellitus
`Prior myocardial infarction
`Prior CVA/TIA
`Left ventricular ejection fraction
`CCS class III or IV
`Worsening exertional angina
`Rest angina
`No. of diseased native coronaries
`Single
`Double
`Triple
`Vein graft age, y (median
`[25th, 75th percentile])
`Values are mean⫾SD or n (%) unless otherwise indicated. CVA indicates
`cardiovascular accident; TIA, transient ischemic attack; and CCS, Canadian
`Cardiovascular Society.
`
`22 (6)
`82 (20)
`298 (74)
`10.4 (6.5, 13.1)
`
`19 (5)
`63 (16)
`311 (79 )
`10.9 (7.2, 14.6)
`
`(P⫽0.024) for GuardWire superiority over conventional
`treatment was met, and the committee recommended early
`termination of the trial on the basis of finding a significant
`benefit for the active arm. An additional 109 patients had
`been enrolled before this could be communicated to all
`investigators, and the present study analysis includes all 801
`randomized patients.
`
`Baseline Demographics
`The baseline demographics are shown in Table 1, reflecting
`the advanced age, severe angina, and multiple risk factors
`common in trials of saphenous aorto-coronary vein graft
`intervention.
`
`Angiographic Findings
`The baseline and postprocedural angiographic data are shown
`in Table 2. They are noteworthy for large graft diameter
`(mean, 3.4 mm), long lesion length (mean, 16 mm; maxi-
`mum, 79 mm), and the common presence of lesion-associated
`thrombus (39%).
`
`Procedural Details
`Stenting was performed in 848 of 875 (96.9%) lesions, using
`either balloon-expandable or self-expanding (9.6% for
`GuardWire-assigned patients and 20.4% for control patients)
`designs. The mean number of stents per lesion was 1.35 and
`1.38 in the GuardWire and control groups, respectively. Most
`involved “primary” stenting—that is, placement of the stent
`without predilatation (79.4% in the GuardWire group and
`67.7% in the control group). Postdilatation after stent deploy-
`ment was performed in 27.3% of GuardWire patients and
`40% of the control patients, using a mean balloon size of
`
`Downloaded from http://ahajournals.org by on July 8, 2019
`
`Page 7
`
`Medtronic Exhibit 1428
`
`

`

`1288
`
`Circulation
`
`March 19, 2002
`
`TABLE 2. Baseline Angiographic Characteristics of 875 Target
`Lesions in 801 Patients With Saphenous Vein Graft Lesions
`Treated by Stenting Assigned to Receive GuardWire Embolic
`Protection or Conventional Guidewire
`
`TABLE 3. Postprocedure Angiographic Characteristics of 875
`Target Lesions in 801 Patients With Saphenous Vein Graft
`Lesions Treated by Stenting Assigned to Receive GuardWire
`Embolic Protection or Conventional Guidewire
`
`Baseline Target Lesion Characteristics
`
`GuardWire
`(n⫽442)
`
`Control
`(n⫽433)
`
`Postprocedure Target Lesion
`Characteristics*
`
`GuardWire
`(n⫽442)
`
`Control
`(n⫽433)
`
`P
`
`79 (18)
`181 (42)
`173 (40)
`
`92 (21)
`196 (44)
`154 (35)
`
`Target graft coronary bypass distribution
`SVG-LAD
`SVG-LCX
`SVG-RCA
`Target vessel angiographic characteristics*
`TIMI flow
`8 (2.0)
`6 (1.5)
`0, 1
`41 (10)
`50 (12)
`2
`361 (88)
`356 (86)
`3
`163 (40)
`157 (38)
`Thrombus appearance
`143 (35)
`160 (39)
`Eccentric target lesion
`Target vessel angulation ⬎45 degrees
`24 (6)
`25 (6)
`3.42⫾0.66
`3.44⫾0.69
`Reference vessel diameter, mm
`1.08⫾0.61
`1.10⫾0.59
`Minimum lumen diameter, mm
`68.7⫾15.8
`68.1⫾15.5
`Percent diameter stenosis, %
`16.6⫾11.17
`15.6⫾9.12
`Lesion length, mm
`Values are mean⫾SD or n (%). SVG indicates saphenous vein graft; LAD, left
`anterior descending; LCX, left circumflex; and RCA, right coronary artery.
`*Angiographic core laboratory data available for 416 GuardWire and 411
`control lesions.
`
`4.2⫾0.7 mm and a mean maximum inflation pressure of
`13.4⫾4.5 atm. Residual minimum lumen diameter
`(3.22⫾0.63 mm in patients stented with the GuardWire and
`3.20⫾0.58 in control patients) and diameter stenosis
`(5.9⫾13.3% in patients stented with the GuardWire and
`6.1⫾11.3% in control patients) were similar (Table 3).
`In the GuardWire arm, technical success was achieved in
`90.1% of cases (henceforth designated as the per-protocol
`cohort). Technical failures included inability to deliver the
`GuardWire to the intended location (5.4%),
`inability to
`achieve or sustain occlusion of antegrade flow (3.2%), and
`inability to perform at
`least 20 mL of aspiration before
`deflation (1.2%). The median GuardWire occlusion time was
`388 seconds (25th and 75th percentiles, 265 and 640
`seconds).
`
`End Point Results
`There was a 6.9% absolute (42% relative) reduction in the
`30-day primary end point (9.6% for GuardWire patients
`versus 16.5% for control patients; P⫽0.004) (Figure 2 and
`Table 4). This predominantly reflects a reduction in myocar-
`dial infarctions of all magnitudes (Figure 3). In addition, rates
`of TIMI grade 3 flow were higher for the GuardWire arm
`(98%) compared with the control arm (95%; P⫽0.04; Table
`3), and the incidence of clinically evident no-reflow was
`reduced (3% versus 9%; P⫽0.001). There was no significant
`increase in subacute closure of the treated graft (1.7% for
`GuardWire versus 0.5% for conventional treatment; P⫽0.18)
`and a lower rate of perforation for the GuardWire arm (0.2%
`versus 1.5%; P⫽0.05) (Table 3).
`
`TIMI flow
`0, 1
`2
`3
`No reflow
`Angiographic distal cutoff
`No reflow or distal cutoff
`Perforation
`Angiographic dissection
`Subacute closure
`Minimum lumen diameter, mm
`Percent diameter stenosis, %
`Values are mean⫾SD or n (%).
`*Angiographic core laboratory data available for 416 GuardWire and 411
`control lesions.
`
`6 (1.5)
`3 (0.7)
`403 (98)
`14 (3)
`9 (2.2)
`20 (4.8)
`1 (0.2)
`9 (4)
`7 (1.7)
`3.22⫾0.63
`5.9⫾13.3
`
`3 (0.7)
`17 (4.2)
`389 (95)
`36 (9)
`13 (3.2)
`40 (9.7)
`6 (1.5)
`4 (1)
`2 (0.5)
`3.20⫾0.58
`6.1⫾11.3
`
`0.51
`0.001
`0.04
`0.001
`0.40
`0.02
`0.05
`0.12
`0.18
`0.56
`0.85
`
`Beyond this intent-to-treat primary end point, a per-
`protocol analysis was performed on the 90.1% of GuardWire
`patients with technically successful

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket